Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verastem Inc (VSTM)

Verastem Inc (VSTM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 707,826
  • Shares Outstanding, K 66,776
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -130,640 K
  • EBIT $ -160 M
  • EBITDA $ -160 M
  • 60-Month Beta 0.41
  • Price/Sales 67,176.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 169.38% (-13.97%)
  • Historical Volatility 101.99%
  • IV Percentile 70%
  • IV Rank 39.87%
  • IV High 333.55% on 04/08/25
  • IV Low 60.53% on 12/10/24
  • Expected Move (DTE 13) 1.87 (18.05%)
  • Put/Call Vol Ratio 2.19
  • Today's Volume 303
  • Volume Avg (30-Day) 336
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 22,432
  • Open Int (30-Day) 22,400
  • Expected Range 8.49 to 12.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.44
  • Number of Estimates 2
  • High Estimate -0.32
  • Low Estimate -0.57
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +66.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.29 +42.11%
on 11/14/25
10.82 -4.26%
on 11/26/25
+2.20 (+26.96%)
since 11/05/25
3-Month
6.98 +48.42%
on 10/20/25
10.82 -4.26%
on 11/26/25
-0.41 (-3.81%)
since 09/05/25
52-Week
3.45 +199.86%
on 12/30/24
11.24 -7.87%
on 09/05/25
+5.11 (+97.33%)
since 12/05/24

Most Recent Stories

More News
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 10.36 (-2.26%)
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of its previously announced...

VSTM : 10.36 (-2.26%)
Verastem Oncology Announces Proposed Public Offering of Common Stock

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell shares...

VSTM : 10.36 (-2.26%)
Verastem Oncology to Present at Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled...

VSTM : 10.36 (-2.26%)
Verastem: Q3 Earnings Snapshot

Verastem: Q3 Earnings Snapshot

VSTM : 10.36 (-2.26%)
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Achieved AVMAPKIâ„¢ FAKZYNJAâ„¢ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported;...

VSTM : 10.36 (-2.26%)
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors

First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in patients with...

VSTM : 10.36 (-2.26%)
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference...

VSTM : 10.36 (-2.26%)
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma

GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose ...

VSTM : 10.36 (-2.26%)
B. Riley Securities Reaffirms Their Buy Rating on Verastem (VSTM)

In a report released today, Kalpit Patel from B. Riley Securities reiterated a Buy rating on Verastem, with a price target of $16.00. The company’s shares closed yesterday at $9.24.Elevate Your Investing...

VSTM : 10.36 (-2.26%)

Business Summary

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib...

See More

Key Turning Points

3rd Resistance Point 10.99
2nd Resistance Point 10.84
1st Resistance Point 10.60
Last Price 10.36
1st Support Level 10.22
2nd Support Level 10.07
3rd Support Level 9.83

See More

52-Week High 11.24
Last Price 10.36
Fibonacci 61.8% 8.27
Fibonacci 50% 7.35
Fibonacci 38.2% 6.43
52-Week Low 3.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar